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Application of Pattern Recognition Techniques for
Classification of Pediatric Brain Tumors by In Vivo
3T 1H-MR Spectroscopy—A Multi-Center Study
Niloufar Zarinabad ,1,2 Laurence J. Abernethy,3 Shivaram Avula,3
Nigel P. Davies,1,2,4 Daniel Rodriguez Gutierrez,5,6 Tim Jaspan,5,7
Lesley MacPherson,2 Dipayan Mitra,8 Heather E.L. Rose,1,2 Martin Wilson,9
Paul S. Morgan,5,6,10 Simon Bailey,11 Barry Pizer,12 Theodoros N. Arvanitis,2,13
Richard G. Grundy,5 Dorothee P. Auer,5,7,10 and Andrew Peet1,2*
Purpose: 3T magnetic resonance scanners have boosted clin-
ical application of 1H-MR spectroscopy (MRS) by offering an
improved signal-to-noise ratio and increased spectral resolu-
tion, thereby identifying more metabolites and extending the
range of metabolic information. Spectroscopic data from clini-
cal 1.5T MR scanners has been shown to discriminate
between pediatric brain tumors by applying machine learning
techniques to further aid diagnosis. The purpose of this multi-
center study was to investigate the discriminative potential of
metabolite profiles obtained from 3T scanners in classifying
pediatric brain tumors.
Methods: A total of 41 pediatric patients with brain tumors
(17 medulloblastomas, 20 pilocytic astrocytomas, and 4
ependymomas) were scanned across four different hospitals.
Raw spectroscopy data were processed using TARQUIN.
Borderline synthetic minority oversampling technique was
used to correct for the data skewness. Different classifiers
were trained using linear discriminative analysis, support
vector machine, and random forest techniques.
Results: Support vector machine had the highest balanced
accuracy for discriminating the three tumor types. The bal-
anced accuracy achieved was higher than the balanced accu-
racy previously reported for similar multi-center dataset from
1.5T magnets with echo time 20 to 32 ms alone.
Conclusion: This study showed that 3T MRS can detect key
differences in metabolite profiles for the main types of child-
hood tumors. Magn Reson Med 000:000–000, 2017. VC 2017
International Society for Magnetic Resonance in Medicine.
Key words: MR spectroscopy; 3T; pediatric brain tumors;
diagnosis; classification
INTRODUCTION
Brain tumors are a significant cause of death and long-term
disability in children, with a range of treatment options and
outcomes depending on the tumor type, location, and age of
the patient. Histopathology following biopsy or surgical
resection is the current gold standard for diagnosis of brain
tumor type and grade (1). Although surgical resection is
often appropriate for many tumors and also provides a his-
tological diagnosis, there are distinct advantages to having a
diagnosis before surgery. A pre-operative diagnosis can
influence the extent of surgical resection attempted, allow
the timely planning of adjuvant treatment and aid discus-
sions with the family. Conventional magnetic resonance
imaging (MRI) is commonly used to propose a diagnosis
before surgery but is of limited accuracy. A previous study
reviewed the radiological reports from a cohort of children
with medulloblastoma, pilocytic astrocytoma, or ependy-
moma and showed an accuracy of diagnosis of 66% (2).
MRI techniques have significantly advanced in recent
years with new imaging techniques being able to provide
information on tissue properties, structure, and basic meta-
bolic processes. Amongst these new techniques, 1H-MR
spectroscopy (MRS) has the ability to provide non-invasive
measurements of metabolite profiles with the potential to
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aid diagnosis and improve the characterization of pediatric
brain tumors (3–8).
Spectroscopic studies on pediatric brain tumors have
attempted to characterize different histologic types and
predict the degree of malignancy (7,9). Non-invasive grad-
ing is especially important for tumors in the eloquent areas
or deeply located tumors. Single and multi-center studies
have worked on development and optimization of diag-
nostic classifiers of childhood brain tumors using MRS.
This has yielded promising results in discriminating
between certain common tumor types (6,7).
With the integration of 3T MRI into clinical practice,
there is growing interest in the practical improvement of
MRS at a 3T field strength over the more established
magnetic field strength of 1.5T, because both the spectral
resolution and the spatial resolution depend, in a linear
fashion, on the magnetic field (10–12).
Although single-voxel MRS of the human brain has
been carried out at many field strengths (from 0.5T to
7T), to date, no study has been reported on application
of pattern recognition techniques for classification of
pediatric brain tumors using 3T MRS.
The aim of this study was to evaluate the discrimina-
tive potential of metabolites obtained from 3T MRI scan-
ners in classifying pediatric brain tumors by comparing




This study included 52 patients less than 16 years of age
(8.26 5.32 years, 21 female and 31 male) with histologi-
cally proven brain tumor collected from four centers in the
United Kingdom. Patient data were collected retrospec-
tively from children who underwent single-voxel MRS
between November 2009 and April 2016 during a routine
MRI for a suspected brain tumor before treatment.
The enrolled cohort consisted of patients with three dif-
ferent tumor types from all regions of the brain, including
medulloblastoma (MB) (n¼ 18), pilocytic astrocytoma (PA)
(n¼ 26), and ependymoma (EP) (n¼ 8). Histopathological,
clinical, and radiological features were used to form a diag-
nosis agreed by a multidisciplinary team. Approval was
obtained from the research ethics committee and informed
consent given by parents/guardians.
Data Acquisition
All studies were performed using 3T scanners from
different manufacturers (Philips Achieva, Siemens MAG-
NETOM Verio). MRS was performed after conventional
MRI that included T1- and T2-weighted and T1-weighted
post-contrast sequences. Spectroscopy images were
acquired using a point resolved single voxel spectros-
copy (PRESS) sequence (time echo¼ 30–46 ms, pulse
repetition time¼2000 ms). Cubic voxels size varied
from 3.38 cm3 to 8 cm3 and 128 repetitions were used. A
water unsuppressed acquisition was also acquired as a
concentration reference. Conventional MRI was used for
guiding voxel placement to ensure it is entirely located
within the tumor
MRS Processing
Raw spectroscopy data were processed using TARQUIN
(version 4.3.6) (13) fitting to a linear combination of 19
metabolite basis functions generated at the correct field
strength and echo time with an additional 9 lipid and mac-
romolecular components (13–15). Frequency alignment,
zero order phase correction, baseline correction, and water
removal using Hankel singular value decomposition
(HSVD) methods were applied by TARQUIN. TARQUIN
determines the chemical shift offset, phase, and baseline
during the fitting process. It then zero fills the time
domain data by a factor of 2 (2) and converts the time
domain signal to spectral domain using a Fourier trans-
form. The obtained spectra are then resampled to
0.49Hz/point. This is to ensure all cases have a consis-
tent Hz/point. The resampled spectra are used for analy-
sis in this study. The full spectral range (3.00 to 12.5
ppm) was used for fitting the data and metabolite quanti-
tation. Quantitation was carried out relative to a water
reference spectrum. Corrections for T2 relaxation times
of metabolites and water were applied as the default val-
ues for TARQUIN (16). To include the metabolites of
interest in the study, main metabolites in 0.5 to 4 ppm
region were used for classification.
Out of 52 enrolled cases, 41 cases (medulloblastoma
n¼ 17, pilocytic astrocytoma n¼20, and ependymoma
n¼ 4, of which 1 is analplastic ependymoma) passed the
following quality control criteria: signal-to-noise ratio
obtained from TARQUIN (SNR)4 (here SNR is defined as
ratio between the maximum in the spectrum minus baseline
divided by 2 root-mean-square of the spectral noise level),
full-width half-maximum obtained from TARQUIN
(FWHM)0.15ppm, stable baseline, good phasing, ade-
quate water suppression, and absence of artefacts. The voxel
position was also reviewed to ensure it was positioned over
tumor, did not include significant amounts of normal-
appearing brain or cyst, and was at least 3mm away from
lipid-containing bone and scalp. The 11 failed cases include
medulloblastoma n¼ 1, pilocytic astrocytoma n¼ 6, and
ependymoma n¼ 4. A poor voxel placement that included
normal brain, small voxel size, and low quality spectra were
the main quality control failure reasons for the latter cases.
For the quantified metabolite profiles, Crammer-Rao lower
bounds were calculated to evaluate metabolite accuracy. All
metabolites where at least two patients had a Crammer-Rao
lower bound< 50 were included (alanine, aspartate and
GABA were excluded) (7). The following metabolites were
used for classification: citrate (Cit), glucose (Glc), glutamine
(Gln), glutathione (Glth), glutamate (Glu), glycine (Gly),
myo-inositol (mIns), lactate (Lac), total choline (tCho¼
glycerophosphocholine [GPC]þphosphocholine [PCh]),
scyllo-inositol (scyllo), taurine (Tau), total creatine
(tCr¼CrþPCr), and total NAA (tNAA¼NAAþNAAG).
The nine macromolecular and lipid components were
grouped together to account for three broad resonances at
0.9ppm (tLM09), 1.3ppm (tLM13), and 2.0ppm (tLM20),
giving a maximum of 16 variables.
The Kruskal-Wallis test for the analysis of variance
(a¼ 0.05) was applied to determine the significant differ-
ences in metabolite concentrations between the three
groups. Mann-Whitney U tests were carried out to
2 Zarinabad et al.
compare mean metabolite values between individual
pair of groups. Statistical analysis was carried out using
SPSS statistics software (version 21.0).
Classification
Borderline synthetic minority oversampling technique
(bSMOTE) (17) was used to overpopulate the original
ependymoma group by 100% and correct for the skew-
ness and class imbalance in the original data. Over-
sampled ependymoma was added to the original data
sets to create an overpopulated metabolite feature set.
Principal component analysis was used to reduce
dimension of this overpopulated set and extract fea-
tures that best discriminate between the three tumor
groups.
Classifiers were trained using linear discriminative
analysis (LDA), support vector machine (SVM), and ran-
dom forest (RF) approaches. These techniques have low,
medium, and high model flexibility, respectively. A
radial basis (Gaussian) function kernel was chosen for
SVM. LDA was trained using diagonal linear learner
where all classes have the same diagonal covariance
matrix.
Developed classifiers using the bSMOTE-overpopulated
sets were tested using the original data and the validity of
the classifier was checked by comparison with the known
histological assignment. Ten-fold cross-validation was
used to evaluate the learning algorithm performance. To
evaluate classifiers trained using bSMOTE data, the origi-
nal data set is partitioned into z5 10 pools in which one
pool is used for evaluation while the remaining z 1 pools
are added to the bSMOTE ependymoma cases, obtained
from oversampling ependymoma cases in the remaining
z  1 pools, and used for training to produce mean error
rates, where z 2 f1; 2; . . . ; Zg. The pools were then ran-
domly rotated and the subsampling and permutation tests
were repeated until all pools had been evaluated exactly
Table 1
Estimated Metabolite Concentration6SD Calculated by TARQUINa.
Metabolite Ependymoma (n¼4) Medulloblastoma (n¼17) Pilocytic Astrocytoma (n¼20) P-Value
Cit* 0.966 0.21 0.566 0.31 0.476 0.48 0.031
Glc 1.26 0.27 2.36 1.7 1.076 1.06 0.073
Gln 1.696 0.11 2.66 1.53 2.26 2.6 0.429
Glth* 1.126 0.32 1.86 0.8 0.666 0.6 <0.000
Glu 1.146 0.94 2.46 2.2 3.26 2.3 0.055
Gly* 1.926 0.5 3.76 2.08 0.736 0.76 <0.000
mIns 4.536 2.3 2.296 1.66 1.946 1.73 0.097
Lac* 1.396 0.68 1.656 1.7 0.656 0.74 0.041
Scyllo* 0.0086 0.01 0.376 0.47 0.056 0.08 0.009
Tau* 0.66 0.75 6.36 4.1 1.076 1.03 <0.000
tNAA* (tNAA¼NAAþNAAG) 0.536 0.25 1.036 0.44 1.376 0.95 0.007
tCho* 1.696 0.29 3.946 1.74 1.46 0.709 <0.000
tCr* 1.696 0.79 3.916 1.5 2.296 2.22 0.003
tLM09 3.76 1.4 4.946 2.4 3.026 1.87 0.084
tLM13* 21.46 10.05 19.326 13.01 7.86 3.7 <0.000
tLM20 7.26 1.8 7.536 4.1 6.36 3.4 0.444
Cit, citrate; Glc, glucose; Gln, glutamine; Glth, glutathione; Glu, glutamate; Gly, glycine; Lac, lactate; mIns, myo-inositol; NAA,N-acetylaspartate;
NAAG,N-Acetylaspartylglutamic acid; scyllo, scyllo-inositol; SD, standard deviation; Tau, taurine; tNAA, total N-acetylaspartate; tCho, total cho-
line; tCr, total creatine; tLM09, lipids and macromolecules 0.9; tLM13, lipids and macromolecules 1.3; tLM20, lipids and macromolecules 2.0.
aThe P-value of analysis of variance (calculated using Kruskal-Wallis test with a¼0.05) is comparing ependymoma versus medullobas-
toma versus pilocytic astrocytoma.
*Metabolites with P-values less than 0.05.
Table 2
Differentiation between Tumor Metabolite Profiles at 3T Comparing
Those that Are Often Included in Differential Diagnoses on







Medulloblastoma (n¼17) # Cit* " Glc**
" tCho** " Glth***
" tCr** " Gly***
" Tau** " Lac*













Cit, citrate; Glc, glucose; Glth, glutathione; Glu, glutamate;
Gly, glycine; Lac, lactate; mIns, myo-inositol; scyllo, scyllo-inositol;
Tau, taurine; tNAA, total N-acetylaspartate; tCho, total choline;
tCr, total creatine; tLM 09, lipids and macromolecules 0.9; tLM 13,
lipids and macromolecules 1.3.
*P0.05; **P<0.01; ***P<0.001.
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once. This ensured that there were no bSMOTE ependy-
moma cases in any of the test sets. The analysis have been
repeated 100 times and results been averaged.
G-mean and F-measure metrics were used for more
precise performance evaluation in class imbalance learn-
ing. The balanced accuracy rate (BAR) of the learning
algorithm, calculated as the mean of the accuracies
for the three tumor types, is also reported here as a
performance measure metric. In this study, all learn-
ing algorithms were developed in python 2.7 (Python
Software Foundation, Wilmington, DE) using Scikit-
learn (Version 0.16.1) and Orange (Version 2.6a2)
libraries.
RESULTS
Mean metabolite concentrations (mM)6 standard devia-
tions (SD) for each diagnostic group are represented in
Table 1. Analysis of variance revealed significant differ-
ences between ependymoma, pilocytic astrocytoma, and
medulloblastoma in ten of the individual metabolites and
combined macromolecules and lipids at 1.3ppm. Glc, Gln,
Glu, mIns, tLM09, and tLM20 had P-values> 0.05. Results
comparing metabolites between specific pairs of tumor
types are reported in Table 2. MB demonstrated increased
Tau and decreased mIns compared to EP. Compared with
PA, MB had a number of significantly higher metabolites
including tCho, Tau, scyllo, tCr, Gly, Glth, and tLM1.3.
Compared with EP, PA demonstrated elevated tNAA and
decreased tLM13 and mIns. Mean MRS spectra of the three
tumor types is presented in Figure 1.
Principal component analysis was carried out and princi-
pal components accounting for 95% of variance were
extracted, giving four principal components. Figure 2 shows
the three-dimensional scatter plot of the three tumor groups
using the first three principal components. Data points of
each tumor types demonstrated a good degree of data cluster-
ing and separation. The four principal components were
then submitted to SVM, RF, and LDA learning algorithms
and classifiers were compared in view of their performance.
The bar plot in Figure 3 characterizes PCA loadings of
the metabolite set for the four main components. tLM13
has dominated the first principal component. Except Glu
and tNAA, all loadings on the first principal component
are positive. tLM20, Tau, Gly, tCho, and tCr were highly
loaded on the second principal component. For the third
principal component, Glc, Glu, mIns, tLM20, and Tau
with a negative load were the most dominant. In the
fourth principal component, the majority of the
FIG. 1. Mean 3T short time echo spectra for (a) ependymoma
(n¼4), (b) medulloblastoma (n¼17), and (c) pilocytic astrocytoma
(n¼20) with solid black line indicating the mean spectra and SD
indicated by the shaded region.
FIG. 2. 3D scatter plot presents principal component analysis (PCA)
space for the discrimination of medulloblastoma (MB), pilocytic
astrocytoma (PA), and ependymoma (EP).
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metabolites were negatively loaded, however, except
Gln, they all were <0.4.
BAR of the learning algorithms and their correspond-
ing individual tumor types, F-measure and G-mean, are
presented in Table 3. SVM (BAR¼0.86) performed favor-
ably in comparison to RF (BAR¼ 0.84) and LDA
(BAR¼ 0.81) in discriminating between the three tumor
types. Figure 4 represents the BAR for the three pattern-
recognition techniques with their accuracy in discrimi-
nating individual tumor groups. To further evaluate and
describe the differences between the three learning algo-
rithms performance, analysis of variance was carried out
on the BAR data obtained from 100 runs of samplings.
The three methods showed to have BAR mean of signifi-
cantly different from each other (P< 0.0001) (Fig. 5). RF
had higher variance (s2¼ 0.002) in comparison to the
LDA (s2¼0.0016) and SVM (s2¼0.0011).
Comparing methods in view of their performance in
classifying EP, all methods had similar accuracy (EP
accuracy¼ 0.75) and misclassified one case as PA.
FIG. 3. The Bar plot represents the PCA loadings of the metabolite sets for the main principal components demonstrating how the principal
components are loaded with the metabolites features.
Table 3
Balanced Accuracy Rate (BAR) of the Pattern Recognition Techni-
ques along With Individual Tumor Type F-Measure and G-Mean.
BAR
F G-Mean
EP MB PA EP MB PA
LDA 0.81 0.54 0.82 0.9 0.52 0.84 0.91
SVM 0.86 0.85 0.9 0.9 0.86 0.9 0.9
RF 0.84 0.75 0.9 0.87 0.76 0.84 0.87
LDA, linear discriminate analysis; RF, Random forest; SVM, sup-
port vector machine; MB, medulloblastoma; PA, pilocytic astrocy-
toma; EP ependymoma.
FIG. 4. Bar plots represent individual tumor group classification
accuracy along with their balanced accuracy comparing performance
of the pattern recognition techniques.
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However, EP F-measure and G-mean varied amongst the
three methods with SVM having the highest values. This
finding demonstrates SVM’s better ability in balancing
the classification performance between the three groups
in comparison to the other two methods.
For PA, SVM, and LDA achieved the highest accuracy
(F-measure¼ 0.9, PA accuracy¼ 0.95). For the MB group,
both SVM and RF had highest number of correctly classi-
fied cases (F-measure¼ 0.9, MB accuracy¼0.88). The
misclassification spread across different tumor types,
data sites, and scanner types is summarized in Table 4.
The 3D scatter plot in Figure 6 represents LDA and
SVM estimated regions. SVM provided improved esti-
mated class boundaries for the three tumor groups that
resulted in less overlap between clustered data points
and estimated regions from dissimilar tumor types. This
difference is more apparent in MB where three cases
assigned incorrectly by LDA were correctly classified by
SVM.
DISCUSSION
This is the first multi-center study investigating 3T MRS
and pattern classification for pediatric tumors. Data rep-
resented here are from four different centers collected
from 3T scanners at short echo time from three common
types of childhood tumors.
Mean metabolite concentrations were shown to differ
between tumor types with some individual metabolites
differing significantly (Mann-Whitney U test P< 0.05)
between specific pairs of tumors. The metabolites identi-
fied to be significantly different between the three tumor
types at 3T in this study generally agrees with previously
reported metabolites for the same tumors at 1.5T (6).
FIG. 5. Comparison of the three learning algorithms balanced accuracy
rate. Box plot represents the distribution of BAR obtained from 100
runs of oversampling.
Table 4
Summary of the Misclassification Spread across Different Tumor Types, Data Sites, and Scanner Types.
Tumor type Ependymoma Medulloblastoma Pilocytic astrocytoma












Hospital Alder Hey Children’s
Hospital (Liverpool)
Nottingham Children’s Hospital
Scanner manufacturer Philips Philips, Siemens Philips
FIG. 6. Three-dimensional scatter plot shows the data clustering for the different tumor types with (a) LDA and (b) SVM decision boundaries.
The graph is oriented so that each clustering can be seen form the best angle with a clear boundary.
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Exceptions are metabolites such as Glc, Glu, tLM09, and
tLM20 that were reported to be significantly different at
1.5T, and Lac that was found to be significantly different
at 3T.
For the 3T data set under study, tCho was higher
(P¼ 0.01) in MB compared to PA in agreement with tCho
as an indicator of cell proliferation and tumor malig-
nancy (18). EP and MB had higher concentrations of lip-
ids and macromolecules compared with PA that is
associated with hypoxia, apoptosis, and necrosis and
linked to high malignancy and poor survival (3,19). Tau
concentration was significantly higher in MB than PA
(P¼ 0.0001) and EP (P¼0.001) (20,21). Similarly mIns
concentration was significantly higher in EP than MB
and PA (P¼ 0.05).
Glc and Glu were not significantly different between
the three tumor types as reported in pervious 1.5T stud-
ies, but Lac was significantly different between PA and
MB (P¼ 0.05). This finding can be because of difference
in sample size or increased resolution at 3T allowing
more accurate quantitation.
Applying pattern recognition techniques to the metab-
olite profile data, a maximum balanced accuracy of 86%
was achieved for discriminating between astrocytoma,
ependymoma, and medulloblastoma. High classification
rates are seen despite the relatively small number of
cases used to train the classifiers and the inclusion of
data from more than one scanner type. The achieved
accuracy was better than the reported BAR obtained
from short time echo 1.5T data from ten different inter-
national centers where similar tumor types and similar
data skewness were studied (6). Using LDA for classifica-
tion, Vicente et al. (6) reported a BAR of 0.79 for tumors
from all regions of the brain. However, the reported 1.5T
BAR for LDA is in a very close agreement with LDA
accuracy when 3T data is used (3T LDA BAR¼ 0.81).
The discrimination power of the pattern recognition
techniques in classifying the ependymoma group alone
was on average 75%. This is mainly because of the
imbalanced nature of the data. Although SMOTE was
used to overpopulate the ependymoma group by 100%
to correct for this skewness, the data distribution still
remained imbalanced because of the small number of
tumors in this group.
In comparing the performance of different pattern recog-
nition techniques, SVM was a fast, easily trained, and reli-
able discriminator with the highest balanced accuracy
rate. This method, with medium flexibility, avoids under-
or overfitting of the data. SVMs strongly draw on variation
methods in their construction and are designed to yield
the best estimate of the optimal separating hyperplane
(Fig. 6b). SVM outperforms conventional pattern recogni-
tion methods especially when the number of training data
is small and number of input variables is large. This is
because the conventional pattern recognition methods do
not have the mechanism to maximize the margins of class
boundaries. Therefore, if some mechanism is introduced
to maximize the margins, the generalization ability is
improved (22).
Future work should focus on optimizing pattern recog-
nition techniques to classify a wider range of tumor
types using 3T MRS. Moreover, a separate prospective
study based on an independent test set to ascertain the
accuracy of non-invasive prognostic biomarkers, espe-
cially for the minority class, provided by 3T MRS is
required.
In conclusion, this study demonstrates the ability
and high diagnostic accuracy of 3T MRS in detecting key
differences in the metabolite profiles for the main types of
childhood tumors. Classification performance of 3T MRS
compares favorably with previously reported multi-center
data sets at 1.5T. 3T MRS with automated processing and
pattern recognition providing a useful technique for accu-
rate, non-invasive diagnosis and classification of child-
hood brain tumors and thereby a powerful diagnostic tool
for clinical practice.
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